RECRUITING

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Description

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Conditions

Cystic Fibrosis (CF)
Talk to us

Related Conditions:

Cystic Fibrosis (CF)

Study Overview

On this page

Study Details

Study overview

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Ensuring Access to Optimal Therapy in Cystic Fibrosis: The ENACT Study

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Condition
Cystic Fibrosis (CF)
Intervention / Treatment

-

Contacts and Locations

Little Rock

Arkansas Children's Hospital, Little Rock, Arkansas, United States, 72205

Seattle

University of Washington, Seattle, Washington, United States, 72205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype
  • * age 2 years and older
  • * ability to provide written informed consent and/or assent (by subject and/or legal guardian)
  • * on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1
  • * clinically stable lung disease, defined as no documented acute decrease in FEV1 \> 10%, OR use of additional antibiotics (intravenous \[IV\] or oral \[PO\]) within 4 weeks prior to screening
  • * recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening
  • * pregnant or breastfeeding female
  • * history of alcohol or substance abuse in the 6 months prior to screening
  • * participation in a study involving an investigational intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening
  • * in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation

Ages Eligible for Study

3 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Arkansas Children's Hospital Research Institute,

Jennifer S Guimbellot, Medical Degree and License, PRINCIPAL_INVESTIGATOR, Arkansas Children's Hospital Research Institute

Study Record Dates

2030-12